Cipla Share Price Live Updates: Cipla's Stock Update
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
12 hours ago
- Business Standard
Q1 results today: Kotak Mahindra, IDFC First Bank among 38 firms on July 26
Kotak Mahindra Bank, IDFC First Bank, Whirlpool of India, and ZEN Technologies are scheduled to announce their earnings report for Q1FY26 today. A host of other companies are also expected to declare their Q1 results today include Balkrishna Industries, Affle 3I, Rainbow Children's Medicare, SBFC Finance, Lodha Developers, and Jain Irrigation Systems. Q1 results highlights from July 25 Cipla: Pharma major Cipla reported a 10 per cent year-on-year (Y-o-Y) rise in its consolidated net profit, which stood at ₹1,297 crore for Q1FY26, up from ₹1,177 crore in the same period last year. Revenue from operations grew 3.2 per cent Y-o-Y to ₹6,837 crore, compared to ₹6,627 crore a year ago. The growth in profit and revenue was driven by strong performance in the consumer healthcare and generic segments. On a sequential basis, revenue rose 3.6 per cent, while net profit increased by 6.2 per cent. SAIL: Steel Authority of India Ltd (SAIL) posted a net profit of ₹744.6 crore for Q1FY26, registering a sharp year-on-year (Y-o-Y) increase of over 810 per cent from ₹81.8 crore in the corresponding quarter last year. Revenue from operations rose 8 per cent Y-o-Y to ₹25,921.8 crore, up from ₹23,997.8 crore in Q1FY25. The strong growth in profit was driven by improved operational performance and higher realisations. Sequentially, however, net profit declined from ₹1,251 crore in the previous quarter (Q4FY25), while revenue dropped by 12 per cent from ₹29,316.1 crore. Market close highlights from July 25 Indian stock markets ended sharply lower on Friday, July 25, dragged down by weakness in the Bajaj twins — Bajaj Finance and Bajaj Finserv — along with other heavyweight counters. The BSE Sensex closed at 81,463.09, down 721 points or 0.88 per cent, while the NSE Nifty50 settled at 24,837, slipping 225 points or 0.9 per cent. On the BSE, major laggards included Bajaj Finance, Bajaj Finserv, Power Grid, Tech Mahindra, Infosys, and Trent. Sun Pharma was the sole gainer in an otherwise weak session. In the broader market, the Nifty MidCap index declined 1.61 per cent, and the Nifty SmallCap index shed 2.1 per cent. List of firms releasing Q1 FY26 results on July 22 3P Land Holdings Ltd Adarsh Plant Protect Ltd Affle 3I Ltd Archidply Industries Ltd AYM Syntex Ltd Balkrishna Industries Ltd-$ Chembond Chemicals Ltd Chambal Breweries & Distilleries Ltd Cil Securities Ltd Coral Newsprints Ltd Creative Castings Ltd Dolphin Medical Services Ltd Gagan Gases Ltd Howard Hotels Ltd IDFC First Bank Ltd Jagsonpal Pharmaceuticals Ltd Jayant Agro Organics Ltd Jain Irrigation Systems Ltd_DVR Jain Irrigation Systems Ltd Kotak Mahindra Bank Ltd Lodha Developers Ltd Medinova Diagnostic Services Ltd Moneyboxx Finance Ltd Premier Energies Ltd Rainbow Children's Medicare Ltd Ras Resorts & Apart Hotels Ltd Regency Fincorp Ltd Relic Technologies Ltd Rishab Special Yarns Ltd SBFC Finance Ltd SKP Securities Ltd SMC Global Securities Ltd Stratmont Industries Ltd TCC Concept Ltd Vandan Foods Ltd Whirlpool of India Ltd ZEN Technologies Ltd ZF Steering Gear India Ltd-$
Time of India
21 hours ago
- Time of India
Oppn blames govt for not ensuring jobs for locals
Porvorim: Blaming govt for doing little to ensure employment opportunities for locals, legislators on Friday said that private companies continue to flout recruitment norms by hiring workers from other states. Legislators said that with over 1.2 lakh Goan youth registered with the employment exchange, sustainable job opportunities are required to ensure that local youth are gainfully employed. The MLAs pointed out that Goa's unemployment rate is pegged at 19%, one of the highest in the country. Govt said that the employment exchange registrations are inflated as many applicants do not remove their names in the hope of landing a govt job. Congress MLA Carlos Ferreira moved a private member's resolution asking govt to address the issue of unemployment in the state. Ferreira said that govt must ensure that Goans are 'prioritised' in recruitment opportunities. Ferreira also demanded stringent measures to guarantee transparency in the recruitment process, equitable access, and protection of the rights of those already employed. 'Companies like Cipla, which are heavily favoured by govt, are not even hiring locals,' Goa Forward Party MLA Vijai Sardesai said. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Learn How To Write Faster for Work (Find Out Now) Grammarly Learn More Undo by Taboola by Taboola Govt data shows that of about 1.4 lakh cards issued under the Labour Smart Cards Scheme, 65,871 are Goan holders and 73,844 are from other states. Goa Investment Promotion Board approved 17 projects promising 9,244 jobs, but only 43 jobs were created so far, shows the data. Calling the situation 'grave and unacceptable,' Sardesai demanded the formation of two high-level task forces to prioritise employment. However, labour and employment minister Atanasio Monserrate blamed Goans for not showing interest in private sector jobs.
Economic Times
a day ago
- Economic Times
Cipla targets $1 bn US revenue in FY27
Mumbai: Cipla aims to achieve $1 billion sales in the US by the next fiscal year, driven by the products it has lined up for launch which the Indian drug maker expects will more than compensate for the imminent patent expiry and price erosion on cancer drug Revlimid.'We believe our pipeline should get us closer to the target (of $1 billion) or surpass that by FY27, depending on the launch timing,' managing director and global chief executive Umang Vohra said over an investor call on Friday.'We have plans for all our launches that are coming in to make up for the revenue losses for Revlimid and that will happen in the short to medium term,' he added. The US remains a very attractive market for Cipla. 'We see it as a growth market over the next 3-5 years,' he said. A generic version of Revlimid (lenalidomide) is one of Cipla's top-selling products in the US. As part of an out of court settlement, Cipla manufactures and markets the drug in the US. Analysts said the expiry of the drug's patent is expected to significantly impact Cipla through a reduction in revenue and potential margin pressure. Cipla has a robust pipeline for the US business with respiratory generic Advair closer to commercialisation and is also preparing for launch of generic Symbicort and a couple of inhalation products. It also plans to launch 2–3 peptide assets in monetisation of these launches remains critical for the company to offset the lenalidomide generic sales erosion, according to a report by broking firm sees the respiratory segment and new product launches lined up in the category to be the biggest opportunity for Cipla in the next 12 months. 'We have 3-4 launches coming up for the US alone, we have several coming up for emerging markets and several for India,' he told potential US tariffs on the pharma sector, Vohra said he does not see it having a 'debilitating effect'. There will be an impact, but it will not derail the business, he company on Friday reported a 10% year-on-year increase in consolidated net profit to Rs 1,298 crore for the first quarter ended June. Revenue rose 4% to Rs 6,957 crore and Ebitda was 25.6% of the revenue, the company stated in a filing with stock India business delivered growth of 6% year-on-year, topping Rs 3,000 crore for the first time ever in a quarter, contributing 44% to the total from North America was $226 million (about Rs 1,955 crore) supported by traction in differentiated assets. It launched two generic oncology products in the US in the past quarter: nano paclitaxel vials and nilotinib capsules.'This performance builds on a strong prior year-on-year quarter where we achieved our highest ever US generics revenue,' said the company has signed an agreement to launch its first biosimilar product in the US that is expected in Q2 FY26.'We will in-license a few assets through partnerships in the near term and maybe launch our own biosimilar assets around 2029-2030,' Vohra company is betting big on GLP-1, which controls sugar levels and appetite, and sees it as a 'significant growth driver for its business.''For us the entire GLP 1 category is important rather than looking at individual categories within that. It will shape up in a manner depending on pipeline assets,' said Vohra. Cipla aims to be among the first wave of launchers for the drugs. The company plans to have a hybrid strategy including having its own products as well as through partnerships.
